A top-ranking Democratic senator called into question the therapeutic value of marijuana on Tuesday while also making a broader point about how the federal drug classification system inhibits medical research.
Sen. Dick Durbin (D-IL) made the comments during a Senate Judiciary Committee hearing on the opioid epidemic and federal moves to restrict powerful fentanyl analogues.
Before getting into his views on the potential consequences of permanently placing those opioids in Schedule I of the Controlled Substances Act (CSA), Durbin, the Senate Democratic whip, took a hit at medical cannabis.
“My state just decided in the last few days to make marijuana legal in my state for recreational purposes, starting January 1,” he said, referencing the passage of a cannabis legalization bill through the Illinois legislature last week. “We’ve had medical marijuana. I’ve been to one of those clinics. It was almost a laughing matter.”
“The medical claims they make about marijuana go way beyond anything that’s been proven,” he said. “There are no clinical trials going on.”
Watch Durbin’s medical cannabis comments around 1:00:00 into the video below:
Durbin’s views on medical cannabis and marijuana reform in general are at odds with those expressed by many of his Democratic colleagues—not to mention a majority of voters. He said earlier this year that he opposed criminalizing cannabis use, but he cautioned against the other “extreme” of legalizing the plant.
Legalization advocates took issue with Durbin’s characterization of medical cannabis.
“Senator Durbin’s comments surrounding the efficacy and therapeutic benefits of cannabis are ignorant at best and cruel at worst,” Justin Strekal, political director of NORML, told Marijuana Moment. “There are over 30,000 peer-reviewed studies hosted on pubmed.gov on the effects of cannabis, including many showing declines in cases of opioid abuse and overdose fatalities.”
“If Mr. Durbin is serious about addressing the opioid crisis, then he ought not to disparage the role or lives saved that legal marijuana can play,” Stekal said.
Michael Liszewski, principal of The Enact Group, a lobbying and consulting firm that focuses on cannabis, told Marijuana Moment he agrees that the “Schedule I status has prevented more robust medical cannabis research,” but that “it’s disappointing that Senator Durbin is characterizing it as a ‘laughing matter.'”
“To imply that patients need to look sick enough in order to obtain relief from medical cannabis ignores at least two points: First, many ailments that are treated by medical cannabis are not readily visible to observers, such as Crohn’s, lupus, and PTSD (all of which are qualifying conditions in Illinois). And second, it ignores the very real possibility that these individuals look healthy because their medical cannabis therapy is providing them with benefit.”
David Mangone, director of government affairs and counsel at Americans for Safe Access, also criticized the lawmaker’s remarks.
“Senator Durbin’s comments about the medical cannabis program in Illinois are an insult to the thousands of people in his state’s program who use cannabis as a life-saving medicine,” he told Marijuana moment.
“Ignoring the fact that there are nearly 400 [National Institutes of Health] supervised clinical trials on cannabis either underway or recruiting participants, and comparing cannabis to fentanyl analogues, is disingenuous, ill-informed, and dangerous for public policy,” Mangone said.
While the senator was dismissive of medical cannabis at the hearing, arguing that we “are not establishing whether marijuana is in fact medically appropriate in so many circumstances where they claim they are,” he also said that the Schedule I status of cannabis is the reason, in his view, that evidence about its therapeutic benefits of cannabis is insufficient.
“Why don’t they [research cannabis]? Because we’ve moved marijuana to Schedule I—the same place we’re about to move all fentanyl analogues,” he said.
“Under a blanket Schedule I framework, which is being asked for today, we could imperil research into more powerful naloxone—a stronger and better treatment to save lives of those who have used fentanyl analogues,” he added. “Is that what we want to do? I don’t think so.”
Liszewski said there “simply was no need for the senator to slander medical cannabis therapy while making his valid point about how Schedule I status harms medical research.”
Durbin later questioned the Drug Enforcement Administration’s opioid production quota, stating that there’s no need to manufacture such a high volume of prescription painkillers. In one of his closing remarks, he made a play on a Reagan-era anti-drug message.
It’s time to say no,” he said. “Just say no—to pharma when they want that kind of production.”
Though the senator made his thoughts on the scheduling system clear, he’s so far declined to sign on to legislation that would amend the issue, by rescheduling or descheduling cannabis. In fact, Durbin has only cosponsored two marijuana-focused bills over the course of his 36 years in Congress to date.
One would have required the DEA to conduct clinical trials on cannabidiol (CBD) and later determine whether the compound should be a controlled substance. The other would have allowed defendants in federal court cases to introduce evidence showing that any marijuana activity was in compliance with a state medical cannabis law.
Notably, during his time in the House, Durbin cosponsored the Anti-Drug Abuse Act of 1986, which included provisions that expanded the criminalization of drugs as well as a section tied to the problem he complained about at Tuesday’s hearing. That provision amended the CSA “to provide that controlled substance analogues shall be treated as a schedule I substance.”
“I appreciate Senator Durbin’s comments about limiting federal research,” Don Murphy, director of federal policies for the Marijuana Policy Project, told Marijuana Moment. “I’d feel even better about it if he channeled that energy and interest by putting his name on legislation to fix the problem”
Photo courtesy of Senate Judiciary Committee.
Congresswoman Voices Support For Allowing ‘Safe Supply’ Of Illegal Drugs For Harm Reduction
The freshman congresswoman says lawmakers should pursue providing people with a “safe supply” of drugs after decriminalization is enacted.
By Sessi Kuwabara Blanchard, Filter
Rep. Cori Bush (D-MO) has broken new ground by indicating her support for a safe supply of controlled substances for people who use them, in response to a Filter reporter’s question.
On Tuesday, the Drug Policy Alliance (DPA) held a press conference unveiling the Drug Policy Reform Act of 2021 (DPRA). It featured DPRA co-authors Bush and Rep. Bonnie Watson Coleman (D-NJ), together with DPA board member Dr. Mary Bassett and Neill Franklin, former executive director of Law Enforcement Action Partnership.
The bill will eliminate criminal penalties for possession of any scheduled substance up to quantities to be determined by a novel commission. It additionally invests in substance use disorder treatment and harm reduction services, while, among other things, preventing people being refused employment, housing, federal benefits and immigration status due to a criminal record for drug possession or personal drug use.
“Do we support a safe supply? Yes.”
During the press conference, DPA Executive Director Kassandra Frederique posed Filter’s question to the congresswomen: Do you support medical practitioners prescribing to patients their controlled substances of choice in order to encourage them to divest from the adulterated illicit supply, just as U.S. doctors did in the late 1910s and early 1920s?
Bush gave a clear answer. “Do we support a safe supply? Yes,” she said. She also explained why DPRA does not provide for some form of safe supply policy. “Right now, our focus is to decriminalize.”
Her comment appears to be one of the first, if not the first, public endorsements by a U.S. politician of a safe supply policy. It’s increasingly a priority for progressive drug-user activists in North America, driven by Canadian advocacy, like that of the Drug User Liberation Front.
“We are enthused to have a congressional leader who is willing to support evidence-based, life-saving interventions like safe supply,” Queen Adeyusi, a policy manager at DPA’s Office of National Affairs, told Filter.
Watson Coleman offered promising, albeit inconclusive, thoughts on the safe supply question. Part of the “whole issue of…personal use of substances,” she said, is “how you get them” and how consumers avoid “getting drugs that kill you as opposed to the right drug that you’re looking for.”
(Ensuring consumers have consistent easy access to pharmaceutical-grade drugs—instead of the unpredictable and adulterated illicit supply that’s driving fatal overdoses—has been shown in multiple studies to greatly reduce engagement with the unregulated supply.)
“To have it in the health care realm instead of the criminal realm is what we’re trying to accomplish,” said Watson Coleman.
“Everything that we’re talking about, we’re looking at it from an evidence-based standpoint,” said Bush. “So, making sure we are looking for guidance from people like Dr. Bassett and others.”
Watson Coleman suggested the question of safe supply policy could be one for the planned Commission on Substance Use, Health and Safety to consider, saying it “will be looking at issues of this nature and will be making recommendations to the secretary of Health and Human Services.”
According to a summary of DPRA published by DPA, the commission will provide “recommendations for preventing the prosecution of individuals possessing, distributing or dispensing personal use quantities of each drug for the purpose of subsistence distribution.”
The biggest win for the North American safe supply movement thus far has, according to advocates’ critiques, been largely symbolic: British Columbia’s mostly-unimplemented prescribing guidelines to provide consumers with pharmaceutical alternatives to adulterated street drugs.
A strong grassroots movement for safe supply policy has yet to materialize in the United States, and advocacy organizations like DPA are still developing their strategy. “We do deep work internally and with movement before moving to introduce legislation,” said Adeyusi. “We are working on a safe supply strategy with others, that can include legislation, but we are not ready yet.”
It appears that Bush may be a meaningful ally to such efforts when the time comes.
This article was originally published by Filter, an online magazine covering drug use, drug policy and human rights through a harm reduction lens. Follow Filter on Facebook or Twitter, or sign up for its newsletter.
Photo courtesy of Markus Spiske.
California Senator Previews Next Steps For Psychedelics Bill And Says It’s A Step Toward Decriminalizing All Drugs
A California senator sponsoring a bill to legalize possession of psychedelics in the state says the proposal is a step toward eventually decriminalizing all drugs.
“We want to get there,” he said in a recent meeting with activists and researchers, though he added that it’s possible the broader reform would need to be decided by voters.
Sen. Scott Wiener (D) made the comments last week in a chat hosted by the Psychedelic and Entheogen Academic Council (PEAC), discussing next steps for his psychedelics legislation after it passed in the Senate earlier this month. He said advancing the measure in the Assembly will be “very challenging” due to a number of factors, but he sees progress in the legislature.
It’s also unclear where Gov. Gavin Newsom (D) stands on the reform, he said—though the governor has long been an outspoken opponent of the war on drugs.
“This is the first time that this idea has ever been introduced in the legislature,” Wiener said. “It’s a brand new idea” that “many of my colleagues have never interacted with.”
The bill originally included record sealing and resentencing provisions for people previously convicted of psychedelics possession offenses, but that language was removed in its last committee stop prior to the Senate floor vote as part of an amendment from the sponsor.
Wiener said the reasoning behind that deletion was that the policy “ended up generating a huge price tag” based on a fiscal analysis, but it could be addressed in separate legislation if the main bill passes.
Since clearing the Senate, SB 519 has been referred to two Assembly committees—Public Safety and Health—but the clock is ticking to move it this session. The senator said it must be heard by the panels by July 15, and then it would go the the Appropriations Committee, which would need to take action by late August.
If all goes well, Wiener told the PEAC members that a floor vote in the Assembly would happen in early September. Should the chamber approve it, the bill would go back to the Senate for concurrence on any amendments (or otherwise go right to Newson’s desk). The governor would need to receive the bill by September 10, and then he would have 30 days to act on it.
Assembly passage is far from a given, however. There are “rivalries” and “tensions” between the two chambers, Wiener said, despite the fact that they’re controlled by the same party.
Colleagues in the same chamber might be more willing to “give you a benefit of the doubt in helping you move forward bills,” he said. What’s more, members in the Assembly go up for reelection more frequently than in the Senate, making them less inclined to back novel legislation like the psychedelics proposal.
The senator said one possible amendment that could be expected in the Assembly would be to remove ketamine from the list of psychedelics that would be included in the reform.
“There are disagreements within the psychedelic world on it,” he said. “It might come out. My view as you keep things in until you have to make a give, and that’s one that we could potentially give on. You don’t want to spontaneously give on things without getting some ability to move the bill forward as a result.”
Mescaline, a psychoactive compound derived from peyote and other cacti, is another controversial psychedelic.
It was specifically excluded from the bill’s reform provisions in peyote-derived form, but the possession of the compound would be allowed if it comes from other plants such as “the Bolivian Torch Cactus, San Pedro Cactus, or Peruvian Torch Cactus.”
That decision on the peyote exclusion was informed by native groups who have strongly pushed back against decriminalizing the cacti for conservationist reasons and because of its sacred value for their communities.
If enacted into law, the bill would remove criminal penalties for possessing or sharing numerous psychedelics—including psilocybin mushrooms, DMT, ibogaine, LSD and MDMA—for adults 21 and older.
Marijuana Moment is already tracking more than 1,100 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
The state Department of Public Health would be required to establish a working group “to study and make recommendations regarding possible regulatory systems that California could adopt to promote safe and equitable access to certain substances in permitted legal contexts.” Those recommendations would be due by January 1, 2024.
For psilocybin specifically, the legislation would repeal provisions in California statute that prohibit the cultivation or transportation of “any spores or mycelium capable of producing mushrooms or other material” that contain the psychoactive ingredient.
But this bill, Wiener emphasized at the beginning of the meeting, is ultimately an incremental step to ending the drug war.
“My view is we should be decriminalizing possession and use of all drugs—and we want to get there,” he said. “This is a step just like cannabis [legalization] was a step. And ultimately we may need to go to the voters for the broader drug decriminalization like Oregon.”
For the time being, however, the senator encouraged PEAC members in San Francisco, where lawmakers are more amenable to psychedelics reform, to reach out to people in other areas of the state to apply pressure on their representatives.
Meanwhile, a group of California activists announced plans earlier this year to put an initiative to legalize the use and retail sale of psilocybin on the state’s 2022 ballot. That group, Decriminalize California, said that it would first work to convince lawmakers to pursue reform and then take the issue directly to the people if the legislature fails to act.
The psychedelics effort in the California legislature, which Wiener first previewed back in November, comes as activists are stepping up the push to enact psychedelics reform locally in cities in the state and across the country. The bill notes those efforts in an explanation of the proposal.
The Northampton, Massachusetts City Council passed a resolution in April to deprioritize enforcement of laws against the possession, use and distribution of a wide range of psychedelics such as psilocybin and ayahuasca. It’s the third city in the state to advance the policy change, following Somerville and Cambridge.
These are some of the latest iterations of a national psychedelics reform movement that’s spread rapidly since Denver became the first city to decriminalize psilocybin mushrooms in 2019.
In Oregon, November’s election saw the passage of a historic initiatives to legalize psilocybin mushrooms for therapeutic purposes and more broadly decriminalize possession of all drugs.
The governor of Connecticut signed legislation last week that includes language requiring the state to carry out a study into the therapeutic potential of psilocybin mushrooms.
Texas lawmakers also recently sent their governor a bill to require the state study the medical benefits of psychedelics for military veterans.
A New York lawmaker introduced a bill this month that would require the state to establish an institute to similarly research the medical value of psychedelics.
In Oakland, the first city where a city council voted to broadly deprioritize criminalization of entheogenic substances, lawmakers approved a follow-up resolution in December that calls for the policy change to be adopted statewide and for local jurisdictions to be allowed to permit healing ceremonies where people could use psychedelics.
After Ann Arbor legislators passed a decriminalization resolution last year, a county prosecutor recently announced that his office will not be pursuing charges over possessing entheogenic plants and fungi—“regardless of the amount at issue.”
The Aspen, Colorado City Council discussed the therapeutic potential of psychedelics like psilocybin and proposals to decriminalize such substances at a meeting last month. But members said, as it stands, enacting a reform would be more better handled at the state level while entheogens remain strictly federally controlled.
Seattle lawmakers also recently sent a letter to members of a local task force focused on the opioid overdose epidemic, imploring the group to investigate the therapeutic potential of psychedelics like ayahuasca and ibogaine in curbing addiction.
Photo courtesy of Wikimedia/Mushroom Observer.
New Jersey Attorney General Cracks Down On ‘Gift’ Marijuana Schemes Involving Overpriced Snacks
The attorney general of New Jersey on Tuesday sent warning letters to companies that are effectively circumventing the state’s marijuana laws by “gifting” cannabis in exchange for non-marijuana-related purchases such as overpriced cookies, brownies and stickers.
Gifting is lawful between adults 21 and older under New Jersey’s adult-use cannabis law, but a number of businesses are allegedly taking advantage of that policy by giving away “free” cannabis products to those who purchase other items like snacks and baked goods.
No retail marijuana businesses have been licensed since the state enacted recreational legalization earlier this year, which followed voter approval of a reform initiative during the November 2020 election. Licensing regulations still need to be developed before adult-use shops can open.
Have you heard about businesses that “gift” marijuana w/ the purchase of snacks or other items? This isn’t the kind of cannabis business allowed by NJ’s new law. We’re warning these businesses to stop unlawful practices that could undercut the legal market.https://t.co/pYBODk12DY
— AG Gurbir Grewal (@NewJerseyOAG) June 15, 2021
“In legalizing adult-use cannabis in New Jersey, the Legislature made it clear they were creating a regulated market with restrictions on how that market operates,” Attorney General Gurbir Grewal said in a press release. “Instead of waiting for those regulations to be established, some vendors have decided to move forward on their own, in ways that the law does not allow.”
“Today we’re making it clear that we will not permit these entities to undermine the regulated cannabis marketplace the Legislature created or to compete unfairly with properly licensed cannabis businesses,” he said.
Four Sky High Munchies, Slumped Kitchen LLC, NJGreenDirect.com LLC and West Winds Wellness were targeted with cease and desist letters, which state that the cannabis gifts that they’re offering appear to be central to their business transactions. The non-cannabis items are generally overpriced, the press release notes.
New Jersey’s legalization law establishes the Cannabis Regulatory Commission (CRC) to oversee the market and create licensing rules. CRC Chairperson Dianna Houenou said that the division “is committed to establishing a safe marketplace of cannabis products.”
“Those trying to preempt the rules and transfer unregulated and untested marijuana items jeopardize public health and undermine confidence in the forthcoming regulated cannabis industry,” she said.
“We will not allow vendors to misrepresent what they’re selling,” Kaitlin Caruso, acting director of the state’s Division of Consumer Affairs, said. “Under our consumer protection laws, vendors are subject to fines and penalties for making false or misleading statements about what they’re selling. We have warned these companies about our concerns, and to stop conduct that could violate our laws.”
New Jersey’s attorney general has been proactive about cannabis reform implementation since the legalization bill was enacted.
The day after Gov. Phil Murphy (D) signed bills to legalize and decriminalize marijuana, Grewal directed prosecutors to drop cases for cannabis-related offenses and issued separate guidance for police on how to proceed under the updated laws.
The attorney general also encouraged prosecutorial discretion for marijuana cases in earlier memos prior to the bill’s signing.